| sTRAEs/IMM . | Patients with sTRAEs receiving IMMs, n (%) . | Patients with resolution of sTRAEs after IMMs, n/n (%) . | Median time to resolution after IMMsb,c (range), wk . |
|---|---|---|---|
| Endocrine (n = 30) | 11 (37) | 5/11 (45) | NR (1.6–90.7+) |
| Systemic corticosteroids | 11 (37) | 5/11 (45) | |
| Gastrointestinal (n = 27) | 6 (22) | 5/6 (83) | 2.0 (1.1–3.9) |
| Immunosuppressive agents | 2 (7) | 2/2 (100) | |
| Systemic corticosteroids | 6 (22) | 5/6 (83) | |
| Hepatic (n = 23) | 10 (44) | 8/10 (80) | 7.5 (1.1–57.3+) |
| Immunosuppressive agents | 3 (13) | 2/3 (67) | |
| Systemic corticosteroids | 10 (43) | 8/10 (80) | |
| Pulmonary (n = 6) | 2 (33) | 2/2 (100) | 4.0 (2.1–5.9) |
| Systemic corticosteroids | 2 (33) | 2/2 (100) | |
| Renal (n = 6) | 2 (33) | 1/2 (50) | NR (3.7–20.6+) |
| Systemic corticosteroids | 2 (33) | 1/2 (50) | |
| Skin (n = 34) | 19 (56) | 11/19 (58) | 10.6 (1.1–106.0+) |
| Topical corticosteroids | 15 (44) | 9/15 (60) | |
| Systemic corticosteroids | 6 (18) | 2/6 (33) |
| sTRAEs/IMM . | Patients with sTRAEs receiving IMMs, n (%) . | Patients with resolution of sTRAEs after IMMs, n/n (%) . | Median time to resolution after IMMsb,c (range), wk . |
|---|---|---|---|
| Endocrine (n = 30) | 11 (37) | 5/11 (45) | NR (1.6–90.7+) |
| Systemic corticosteroids | 11 (37) | 5/11 (45) | |
| Gastrointestinal (n = 27) | 6 (22) | 5/6 (83) | 2.0 (1.1–3.9) |
| Immunosuppressive agents | 2 (7) | 2/2 (100) | |
| Systemic corticosteroids | 6 (22) | 5/6 (83) | |
| Hepatic (n = 23) | 10 (44) | 8/10 (80) | 7.5 (1.1–57.3+) |
| Immunosuppressive agents | 3 (13) | 2/3 (67) | |
| Systemic corticosteroids | 10 (43) | 8/10 (80) | |
| Pulmonary (n = 6) | 2 (33) | 2/2 (100) | 4.0 (2.1–5.9) |
| Systemic corticosteroids | 2 (33) | 2/2 (100) | |
| Renal (n = 6) | 2 (33) | 1/2 (50) | NR (3.7–20.6+) |
| Systemic corticosteroids | 2 (33) | 1/2 (50) | |
| Skin (n = 34) | 19 (56) | 11/19 (58) | 10.6 (1.1–106.0+) |
| Topical corticosteroids | 15 (44) | 9/15 (60) | |
| Systemic corticosteroids | 6 (18) | 2/6 (33) |
aIncludes events reported between first dose and 30 days after last dose of study therapy.
bPatients who experienced sTRAEs without worsening from baseline grade were excluded from time to resolution analysis.
cEvents without a stop date or with a stop date equal to the death as well as grade 5 events are considered unresolved.
Abbreviations: IMM, immune‐modulating medications; NR, not reached; sTRAE, select treatment‐related adverse event.
| sTRAEs/IMM . | Patients with sTRAEs receiving IMMs, n (%) . | Patients with resolution of sTRAEs after IMMs, n/n (%) . | Median time to resolution after IMMsb,c (range), wk . |
|---|---|---|---|
| Endocrine (n = 30) | 11 (37) | 5/11 (45) | NR (1.6–90.7+) |
| Systemic corticosteroids | 11 (37) | 5/11 (45) | |
| Gastrointestinal (n = 27) | 6 (22) | 5/6 (83) | 2.0 (1.1–3.9) |
| Immunosuppressive agents | 2 (7) | 2/2 (100) | |
| Systemic corticosteroids | 6 (22) | 5/6 (83) | |
| Hepatic (n = 23) | 10 (44) | 8/10 (80) | 7.5 (1.1–57.3+) |
| Immunosuppressive agents | 3 (13) | 2/3 (67) | |
| Systemic corticosteroids | 10 (43) | 8/10 (80) | |
| Pulmonary (n = 6) | 2 (33) | 2/2 (100) | 4.0 (2.1–5.9) |
| Systemic corticosteroids | 2 (33) | 2/2 (100) | |
| Renal (n = 6) | 2 (33) | 1/2 (50) | NR (3.7–20.6+) |
| Systemic corticosteroids | 2 (33) | 1/2 (50) | |
| Skin (n = 34) | 19 (56) | 11/19 (58) | 10.6 (1.1–106.0+) |
| Topical corticosteroids | 15 (44) | 9/15 (60) | |
| Systemic corticosteroids | 6 (18) | 2/6 (33) |
| sTRAEs/IMM . | Patients with sTRAEs receiving IMMs, n (%) . | Patients with resolution of sTRAEs after IMMs, n/n (%) . | Median time to resolution after IMMsb,c (range), wk . |
|---|---|---|---|
| Endocrine (n = 30) | 11 (37) | 5/11 (45) | NR (1.6–90.7+) |
| Systemic corticosteroids | 11 (37) | 5/11 (45) | |
| Gastrointestinal (n = 27) | 6 (22) | 5/6 (83) | 2.0 (1.1–3.9) |
| Immunosuppressive agents | 2 (7) | 2/2 (100) | |
| Systemic corticosteroids | 6 (22) | 5/6 (83) | |
| Hepatic (n = 23) | 10 (44) | 8/10 (80) | 7.5 (1.1–57.3+) |
| Immunosuppressive agents | 3 (13) | 2/3 (67) | |
| Systemic corticosteroids | 10 (43) | 8/10 (80) | |
| Pulmonary (n = 6) | 2 (33) | 2/2 (100) | 4.0 (2.1–5.9) |
| Systemic corticosteroids | 2 (33) | 2/2 (100) | |
| Renal (n = 6) | 2 (33) | 1/2 (50) | NR (3.7–20.6+) |
| Systemic corticosteroids | 2 (33) | 1/2 (50) | |
| Skin (n = 34) | 19 (56) | 11/19 (58) | 10.6 (1.1–106.0+) |
| Topical corticosteroids | 15 (44) | 9/15 (60) | |
| Systemic corticosteroids | 6 (18) | 2/6 (33) |
aIncludes events reported between first dose and 30 days after last dose of study therapy.
bPatients who experienced sTRAEs without worsening from baseline grade were excluded from time to resolution analysis.
cEvents without a stop date or with a stop date equal to the death as well as grade 5 events are considered unresolved.
Abbreviations: IMM, immune‐modulating medications; NR, not reached; sTRAE, select treatment‐related adverse event.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
